- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.12.24 | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.11.24 | Zenas BioPharma, Inc. GAAP EPS of -$5.02 | 2 | Seeking Alpha | ||
| 12.11.24 | Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | 158 | GlobeNewswire (Europe) | -INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma... ► Artikel lesen | |
| 12.11.24 | Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | 129 | GlobeNewswire (Europe) | -Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-... ► Artikel lesen | |
| 07.11.24 | Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences | 271 | GlobeNewswire (Europe) | WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the... ► Artikel lesen | |
| 08.10.24 | Zenas started at buy by four banks on lead drug potential | 2 | Seeking Alpha | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 08.10.24 | Morgan Stanley bullisch für Zenas Biopharma-Aktie aufgrund zunehmender Dynamik bei obexelimab-Studien | 8 | Investing.com Deutsch | ||
| 08.10.24 | Citi sieht Aufwärtspotenzial für Zenas Biopharma-Aktie aufgrund von Fortschritten bei Obexelimab in wichtigen Studien | 3 | Investing.com Deutsch | ||
| 08.10.24 | Citi sees upside in Zenas Biopharma stock as obexelimab progresses in key trials | 3 | Investing.com | ||
| 08.10.24 | Morgan Stanley bullish on Zenas Biopharma stock as obexelimab trials gain momentum | 4 | Investing.com | ||
| 08.10.24 | Jefferies bullish on Zenas stock as obexelimab advances in autoimmune trials | 1 | Investing.com | ||
| 08.10.24 | Guggenheim setzt auf Zenas-Aktie aufgrund vielversprechender Aussichten für Hauptmedikament Obexelimab | 2 | Investing.com Deutsch | ||
| 08.10.24 | Jefferies zeigt sich bullisch für Zenas-Aktie aufgrund von Fortschritten bei Obexelimab in Autoimmun-Studien | 2 | Investing.com Deutsch | ||
| 08.10.24 | Zenas stock backed by Guggenheim on strong outlook for lead drug obexelimab | 2 | Investing.com | ||
| 21.09.24 | Zenas BioPharma CEO acquires $360k worth of company shares | 1 | Investing.com | ||
| 19.09.24 | Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering | 302 | GlobeNewswire (Europe) | WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas"), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and... ► Artikel lesen | |
| 18.09.24 | Zenas BioPharma director acquires $999k in company stock | 3 | Investing.com | ||
| 17.09.24 | IPO Radar: Applied Nutrition, Zenas BioPharma, BingEx | 2 | The Armchair Trader | ||
| 17.09.24 | Zenas BioPharma director buys $7.48m in company stock | 1 | Investing.com | ||
| 17.09.24 | Zenas BioPharma director Jason Raleigh acquires $15 million in company stock | 4 | Investing.com |
Seite:
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 269,95 | +2,84 % | Granite Group Advisors LLC Has $2.29 Million Holdings in Amgen Inc. (NASDAQ:AMGN) | ||
| REGENERON PHARMACEUTICALS | 655,40 | +1,80 % | Looking Into Regeneron Pharmaceuticals' Recent Short Interest | ||
| BIOMARIN PHARMACEUTICAL | 58,64 | -0,31 % | Why Is Andreas Halvorsen Bullish On BioMarin Pharmaceutical Inc. (BMRN) Now? | ||
| ARROWHEAD PHARMACEUTICALS | 19,155 | -3,26 % | AKTIONÄR-Favorit Arrowhead Pharmaceuticals: Wichtiger Meilenstein | Gute Nachrichten von Arrowhead Pharmaceuticals am Freitagabend. Die US-Gesundheitsbehörde FDA hat den Antrag auf Marktzulassung des Unternehmens für Plozasiran zur Behandlung von Patienten mit einer... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 5,916 | -0,74 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen | |
| ARDELYX | 5,278 | +0,42 % | Hedge Fund and Insider Trading News: David Tepper, Ray Dalio, Josh Resnick, Bill Ackman, Warren Buffett, George Soros, Saba Capital, Ardelyx Inc (ARDX), RH (RH), and More | ||
| SWEDISH ORPHAN BIOVITRUM | 29,260 | +1,18 % | Swedish Orphan Biovitrum AB: Invitation: Sobi's Q4 and FY 2024 report | Sobi plans to publish its report for the fourth quarter and full year of 2024 on 5 February 2025 at 08:00 CET.
STOCKHOLM, Jan. 21, 2025 /PRNewswire/ -- Investors, analysts, and the media... ► Artikel lesen | |
| INSMED | 74,50 | -0,67 % | Insmed Incorporated: Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | BRIDGEWATER, N.J., Jan. 3, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first-... ► Artikel lesen | |
| BENITEC BIOPHARMA | 10,680 | -1,11 % | Benitec Biopharma Inc.: Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update | -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical... ► Artikel lesen | |
| SCHOLAR ROCK | 41,600 | -0,48 % | Scholar Rock (NASDAQ:SRRK) Sets New 12-Month High - What's Next? | ||
| PROQR THERAPEUTICS | 2,018 | -2,23 % | ProQR Therapeutics Aktie: Weg in die Zukunft geebnet! | ProQR Therapeutics, ein niederländisches Biotechnologieunternehmen, zeigt sich trotz herausfordernder Marktbedingungen widerstandsfähig. Die Aktie verzeichnete am 2. November 2024 einen leichten Rückgang... ► Artikel lesen | |
| THERATECHNOLOGIES | 1,630 | +5,16 % | Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV Manufacturing Environment | MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 2,045 | -8,91 % | Ventyx Biosciences, Inc.: Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease | SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 37,200 | +0,54 % | Crinetics upgraded to buy by Jefferies, atumelnant potential cited | ||
| ENSYSCE BIOSCIENCES | 7,510 | -0,40 % | Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR | ~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"... ► Artikel lesen |
ZENAS BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -9,09 % bei einem Aktienkurs von 7,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.
